CG MED EQUIP.
838810
BEOKA
870199
Shenzhen Bromake New Material
301387
4
Zhejiang Hongchang Electrical Technology
301008
5
Wuhan Lincontrol Automotive Electronics Co., Ltd.
688667
CN Stock MarketDetailed Quotes
300253 Winning Health Technology Group
- 10.24
- +0.34+3.43%
Market Closed Apr 30 15:00 CST
22.65BMarket Cap292.57P/E (TTM)
10.40High9.86Low846.96KlotVolume9.98Open9.90Pre Close861.71MTurnover4.43%Turnover Ratio256.00P/E (Static)2.21BShares14.5552wk High3.82P/B19.58BFloat Cap5.1152wk Low11.88Limit Up1.91BShs Float29.03Historical High7.92Limit Down5.46%Amplitude0.61Historical Low0.02Dividend TTM10.17Avg Price351.92KlotAsk0.20%Div YieldTTM100Lot Size466.66KlotBid
Winning Health Technology Group Key Stats
All
YOY
| (Q3)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total operating revenue | -30.24%344.98M | -12.05%2.78B | 0.65%1.91B | 2.68%1.22B | 10.09%494.49M | 2.28%3.16B | 1.60%1.9B | 8.75%1.19B | 0.82%449.17M | 12.46%3.09B |
| Operating revenue | -30.24%344.98M | -12.05%2.78B | 0.65%1.91B | 2.68%1.22B | 10.09%494.49M | 2.28%3.16B | 1.60%1.9B | 8.75%1.19B | 0.82%449.17M | 12.46%3.09B |
| Other operating revenue | ---- | -82.00%444.69K | ---- | --0 | ---- | 79.42%2.47M | ---- | --0 | ---- | 46.27%1.38M |
| Total operating cost | -28.81%379.82M | -10.52%2.51B | -3.75%1.78B | -8.37%1.16B | -8.86%533.56M | -0.70%2.81B | 5.66%1.84B | 23.08%1.26B | 27.01%585.42M | 18.90%2.83B |
| Operating cost | -30.88%226.09M | -6.79%1.62B | 2.59%1.13B | 1.51%717.73M | 7.76%327.09M | -0.04%1.74B | 6.48%1.1B | 16.33%707.07M | 15.69%303.53M | 18.03%1.74B |
| Operating tax surcharges | -15.88%3.49M | -22.02%23.12M | -17.36%14.58M | -5.20%10.07M | 22.22%4.15M | 14.92%29.65M | 12.78%17.65M | -5.72%10.62M | 8.00%3.39M | -1.59%25.8M |
| Operating expense | -31.32%51.62M | -25.18%342.99M | -26.16%240.62M | -31.83%166.9M | -36.96%75.17M | -7.55%458.43M | 9.19%325.89M | 42.27%244.81M | 58.64%119.23M | 28.10%495.87M |
| Administration expense | -25.63%31.83M | 3.57%202.38M | -0.13%140.46M | -7.77%97.84M | -17.45%42.8M | -7.74%195.4M | -9.70%140.65M | 14.26%106.08M | 12.31%51.85M | 6.51%211.8M |
| Financial expense | 9.18%15.55M | 12.45%57.44M | 11.20%42.4M | 12.40%28.27M | 10.81%14.24M | 28.78%51.08M | 20.73%38.13M | 29.52%25.15M | 62.16%12.85M | 11.65%39.66M |
| -Interest expense (Financial expense) | 0.28%16.84M | 4.23%66.76M | 5.99%50.45M | 6.16%33.54M | 7.26%16.79M | 7.42%64.05M | -0.17%47.6M | 0.14%31.59M | 0.09%15.66M | 27.73%59.63M |
| -Interest Income (Financial expense) | 47.85%-1.39M | 25.39%-10.14M | 15.10%-8.63M | 9.69%-6.14M | 11.92%-2.67M | 34.08%-13.59M | 39.03%-10.16M | 45.53%-6.8M | 61.70%-3.04M | -74.74%-20.62M |
| Research and development | -26.93%51.23M | -20.60%264.63M | -6.03%209.22M | -19.32%137.37M | -25.86%70.11M | 6.22%333.3M | 5.18%222.64M | 37.76%170.27M | 42.85%94.57M | 22.73%313.77M |
| Credit Impairment Loss | 119.59%44.44M | -996.56%-86.3M | -185.86%-7.5M | -194.70%-6.55M | 945.06%20.24M | 94.46%-7.87M | 121.52%8.74M | 216.66%6.91M | -61.85%1.94M | 16.33%-141.94M |
| Asset Impairment Loss | -1,901.88%-23.93M | -23.83%-169.31M | 36.49%-64.33M | 5.47%-77.39M | -176.48%-1.2M | -5.99%-136.73M | -28.53%-101.29M | -6.96%-81.87M | -76.42%1.56M | -53.70%-129M |
| Other net revenue | -4.17%35.23M | -1,273.04%-181.89M | -190.73%-13.54M | -357.22%-48.24M | 30.48%36.76M | 94.11%-13.25M | 124.51%14.92M | 144.66%18.75M | -27.05%28.18M | -6,805.45%-224.84M |
| Fair value change income | -106.70%-466.17K | 43.35%-28.59M | 708.20%4.89M | 625.94%6.96M | 250.34%6.96M | -102.76%-50.46M | 86.66%-803.55K | 87.71%-1.32M | 586.19%1.99M | -116.00%-24.89M |
| Invest income | 59.71%-6.6M | -263.56%-48.25M | -252.50%-30.01M | -163.73%-20.89M | -14.28%-16.39M | 144.91%29.5M | 154.73%19.68M | 247.09%32.79M | -39.97%-14.34M | -68.23%-65.68M |
| -Including: Investment income associates | 54.58%-7.44M | 35.15%-20.11M | 29.21%-29.06M | 25.24%-20.89M | -14.28%-16.39M | 33.93%-31.01M | -5.41%-41.05M | -10.51%-27.95M | -39.97%-14.34M | -4.10%-46.93M |
| Asset deal income | -97.76%2.87K | 34.38%-279.42K | 510.69%178.48K | 521.90%174.98K | 10,153.86%128.16K | 17.79%-425.83K | -97.57%29.23K | -97.66%28.14K | --1.25K | -392.98%-518.01K |
| Other revenue | -19.37%21.79M | -1.25%150.84M | -6.02%83.24M | -20.52%49.46M | -27.03%27.02M | 11.34%152.75M | -10.81%88.57M | -3.12%62.22M | -1.45%37.03M | -2.19%137.19M |
| Operating profit | 116.82%387.32K | -74.47%87.17M | 74.39%124.41M | 132.45%17.33M | 97.87%-2.3M | 764.35%341.43M | 10.94%71.34M | -298.32%-53.41M | -565.73%-108.07M | -89.46%39.5M |
| Add:Non operating Income | 160,727.66%10.12K | 56.03%363.92K | -21.36%32.35K | 77.84%7.26K | -99.49%6.29 | 590.52%233.23K | 3.90%41.15K | -96.65%4.08K | -97.56%1.24K | -88.80%33.78K |
| Less:Non operating expense | 5,603.90%1M | -37.04%577.39K | -36.63%545.38K | -44.83%225.98K | -33.85%17.61K | -7.80%917.04K | 27.15%860.59K | -20.64%409.64K | 64.56%26.62K | -44.60%994.62K |
| Total profit | 73.83%-607.2K | -74.48%86.96M | 75.68%123.89M | 131.80%17.11M | 97.85%-2.32M | 784.12%340.75M | 10.76%70.52M | -302.79%-53.82M | -565.14%-108.1M | -89.67%38.54M |
| Less:Income tax cost | 131.06%2.74M | 59.49%36.89M | 66.34%-13.55M | 86.30%-5.1M | 50.74%-8.81M | -2.74%23.13M | -139.26%-40.25M | -417.58%-37.21M | -290.03%-17.89M | 22.38%23.78M |
| Net profit | -151.51%-3.35M | -84.24%50.07M | 24.08%137.44M | 233.79%22.21M | 107.20%6.49M | 2,052.19%317.62M | 37.62%110.77M | -149.23%-16.6M | -752.56%-90.2M | -95.83%14.76M |
| Net profit from continuing operation | -151.51%-3.35M | -84.24%50.07M | 24.08%137.44M | 233.79%22.21M | 107.20%6.49M | 2,052.19%317.62M | 37.62%110.77M | -149.23%-16.6M | -752.56%-90.2M | -95.83%14.76M |
| Less:Minority Profit | 14.73%-8.63M | 6.24%-37.83M | 58.65%-17.19M | 76.04%-7.95M | 62.03%-10.13M | 57.03%-40.34M | 30.20%-41.56M | -0.08%-33.2M | -48.66%-26.67M | -284.14%-93.88M |
| Net profit of parent company owners | -68.18%5.29M | -75.45%87.89M | 1.51%154.63M | 81.83%30.17M | 126.16%16.62M | 229.49%357.96M | 8.79%152.34M | -75.20%16.59M | -300.02%-63.53M | -71.27%108.64M |
| Earning per share | ||||||||||
| Basic earning per share | -68.83%0.0024 | -75.52%0.0408 | 0.99%0.0716 | 81.82%0.014 | 126.01%0.0077 | 228.15%0.1667 | 8.74%0.0709 | -75.32%0.0077 | -300.00%-0.0296 | -71.22%0.0508 |
| Diluted earning per share | -68.83%0.0024 | -75.05%0.0407 | 2.44%0.0713 | 82.89%0.0139 | 126.19%0.0077 | 221.70%0.1631 | 6.75%0.0696 | -75.64%0.0076 | -298.65%-0.0294 | -71.21%0.0507 |
| Other composite income | ||||||||||
| Total composite income | -151.51%-3.35M | -84.24%50.07M | 24.08%137.44M | 233.79%22.21M | 107.20%6.49M | 2,052.19%317.62M | 37.62%110.77M | -149.23%-16.6M | -752.56%-90.2M | -95.83%14.76M |
| Total composite income of parent company owners | -68.18%5.29M | -75.45%87.89M | 1.51%154.63M | 81.83%30.17M | 126.16%16.62M | 229.49%357.96M | 8.79%152.34M | -75.20%16.59M | -300.02%-63.53M | -71.27%108.64M |
| Total composite income of minority owners | 14.73%-8.63M | 6.24%-37.83M | 58.65%-17.19M | 76.04%-7.95M | 62.03%-10.13M | 57.03%-40.34M | 30.20%-41.56M | -0.08%-33.2M | -48.66%-26.67M | -284.14%-93.88M |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion |
| Auditor | -- | Rong Cheng Certified Public Accountants (Special General Partnership) | -- | -- | -- | Rong Cheng Certified Public Accountants (Special General Partnership) | -- | -- | -- | Rong Cheng Certified Public Accountants (Special General Partnership) |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.